Abstract | Transient rapamycin treatment can increase lifespan and healthspan in middle-aged mice

Open accessCopyright infoDownload PDFDownload figures

Transient rapamycin treatment can increase lifespan and healthspan in middle-aged mice

Abstract

Affiliation details

University of Washington, United States; Fred Hutchinson Cancer Research Center, United States; University of Missouri, United States

The FDA approved drug rapamycin increases lifespan in rodents and delays age-related dysfunction in rodents and humans. Nevertheless, important questions remain regarding the optimal dose, duration, and mechanisms of action in the context of healthy aging. Here we show that 3 months of rapamycin treatment is sufficient to increase life expectancy by up to 60% and improve measures of healthspan in middle-aged mice. This transient treatment is also associated with a remodeling of the microbiome, including dramatically increased prevalence of segmented filamentous bacteria in the small intestine. We also define a dose in female mice that does not extend lifespan, but is associated with a striking shift in cancer prevalence toward aggressive hematopoietic cancers and away from non-hematopoietic malignancies. These data suggest that a short-term rapamycin treatment late in life has persistent effects that can robustly delay aging, influence cancer prevalence, and modulate the microbiome.

DOI: http://dx.doi.org/10.7554/eLife.16351.001